XOMA (NASDAQ:XOMA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a $104.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Price Performance

NASDAQ:XOMA opened at $20.90 on Wednesday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The business’s 50-day simple moving average is $24.55 and its two-hundred day simple moving average is $27.24. The stock has a market cap of $246.26 million, a PE ratio of -6.01 and a beta of 1.00. XOMA has a 52 week low of $19.92 and a 52 week high of $35.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, analysts forecast that XOMA will post -1.41 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. New York State Common Retirement Fund grew its position in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 1,183 shares during the period. Bank of America Corp DE boosted its position in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in shares of XOMA during the fourth quarter valued at approximately $206,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.